IFNA17 and non-small cell lung carcinoma: A relevant and very recent study in NSCLC is SLU01, a phase 1/2 randomized, open-label, multicenter trial evaluating the clinical efficacy and safety of DCVAC/LuCa added to standard first-line chemotherapy (paclitaxel and carboplatin) and immune-enhancers (IFN-α and hydroxychloroquine) in patients with stage IV NSCLC (NCT02470468).